AMENDMENT NO. 3 TO JOINT DEVELOPMENT AND OPTION AGREEMENT BETWEEN THE CLEVELAND CLINIC FOUNDATION AND BREATHTECH CORPORATIONJoint Development and Option Agreement • September 20th, 2024 • ASTROTECH Corp • Laboratory analytical instruments • Delaware
This Amendment No. 3 to Joint Development and Option Agreement (this “Amendment”), is made and entered into effective as of November 21, 2023 (the “Amendment Date”), by and between The Cleveland Clinic Foundation (“CCF”) and BreathTech Corporation (“Company”, and together with CCF the “Parties”, and each, a “Party”).
Joint Development and Option AgreementJoint Development and Option Agreement • October 20th, 2020 • ASTROTECH Corp • Laboratory analytical instruments • Delaware
This Joint Development and Option Agreement ("JDA"), effective and binding as of the last date of execution herein ("EFFECTIVE DATE"), is by and between The Cleveland Clinic Foundation (hereinafter referred to along with its AFFILIATEs as "CCF"), an Ohio non-profit corporation with offices located at 9500 Euclid Avenue, Cleveland, Ohio 44195; and BreathTech Corporation, a wholly owned subsidiary of Astrotech Corporation (hereinafter referred to along with its AFFILIATEs as "COMPANY"), a for profit corporation having its principal office at 2028 E. Ben White Blvd. #240-9530, Austin, Texas 78741.
First Amendment To Joint Development and Option AgreementJoint Development and Option Agreement • September 20th, 2024 • ASTROTECH Corp • Laboratory analytical instruments
This First Amendment ("Amendment") is made as of March 23, 2022 ("Amendment Effective Date") by and between The Cleveland Clinic Foundation, an Ohio non-profit corporation located at 9500 Euclid Avenue, Cleveland, Ohio 44195 (hereinafter referred to along with its Affiliates as "CCF"), and BreathTech Corporation, a wholly owned subsidiary of Astrotech Corporation (hereinafter referred to along with its Affiliates as "Company").
Redactions with respect to certain portions hereof denoted with “***” Joint Development and Option Agreement PreambleJoint Development and Option Agreement • March 11th, 2021 • Anixa Biosciences Inc • Pharmaceutical preparations • Ohio
This Joint Development and Option Agreement (“JDA”), effective and binding as of the last date of execution herein (“EFFECTIVE DATE”), is by and between The Cleveland Clinic Foundation (hereinafter referred to along with its AFFILIATEs as “CCF”), an Ohio non-profit corporation with offices located at 9500 Euclid Avenue, Cleveland, Ohio 44195; and Anixa Biosciences, Inc. (hereinafter referred to as “COMPANY”), a Delaware corporation having its principal office at 3150 Almaden Exp., Suite 250, San Jose, CA 95118.
Redactions with respect to certain portions hereof denoted with “***” Joint Development and Option Agreement PreambleJoint Development and Option Agreement • June 4th, 2024 • Anixa Biosciences Inc • Pharmaceutical preparations • Ohio
This Joint Development and Option Agreement (“JDA’’), effective and binding as of the last date of execution herein (“EFFECTIVE DATE”), is by and between The Cleveland Clinic Foundation (hereinafter referred to along with its AFFILIATEs as “CCF”), an Ohio non-profit corporation with offices located at 9500 Euclid Avenue, Cleveland, Ohio 44195; and Anixa Biosciences, Inc. (hereinafter referred to as “COMPANY”), a Delaware corporation having its principal office at 3150 Almaden Exp., Suite 250, San Jose, CA 95118.
